Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29513520 | 0.98 | CYP2A6 (0.57) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL28230938 | 0.89 | RAB9A (0.65) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL17199124 | 0.89 | CYP1A1 (0.60) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL17199123 | 0.89 | PDE10A (0.63) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL31548558 | 0.89 | NPC1 (0.64) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL1465037 | 0.89 | NPC1 (0.64) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL10172983 | 0.87 | CYP2A6 (0.63) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL11003375 | 0.87 | NPC1 (0.62) | CYP2A6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL10173132 | 0.85 | CYP19A1 (0.70) | NPC1RAB9AKDM4EMEN1MAPT | |
| SCHEMBL10222638 | 0.85 | NPC1 (0.46) | CYP2A6KEAP1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197082-A | Anthraquinone-based diamine monomer, magenta intrinsic polyimide derived from same and preparation method thereof | 上海交通大学 | 2022-10-18 | — | — | CN | claimed |
| US-20240207487-A1 | VIABLE BIOENGINEERED ALLOGENEIC CELLULARIZED SKIN CONSTRUCTS THAT SECRETE SOLUBLE FACTORS ASSOCIATED WITH REGENERATIVE WOUND HEALING | GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| EP-4351603-A1 | VIABLE BIOENGINEERED ALLOGENEIC CELLULARIZED SKIN CONSTRUCTS THAT SECRETE SOLUBLE FACTORS ASSOCIATED WITH REGENERATIVE WOUND HEALING | Stratatech Corporation (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261248-A1 | VIABLE BIOENGINEERED ALLOGENEIC CELLULARIZED SKIN CONSTRUCTS THAT SECRETE SOLUBLE FACTORS ASSOCIATED WITH REGENERATIVE WOUND HEALING | STRATATECH CORPORATION (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| CN-107383372-B | Polyimide film with pyrimidine side group and preparation method thereof | 江汉大学 | 2018-07-03 | — | — | CN | disclosed |
| CN-107383372-A | Polyimide film with pyrimidine side base and preparation method thereof | 江汉大学 | 2017-11-24 | — | — | CN | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-5733762-A | CONJUGATED GLYCOPROTEINS FOR DRUG DELIVERY | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1998-03-31 | — | — | US | disclosed |
| US-5595897-A | CATIONIC POLYMERS | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP2A6 1242/4885KEAP1 38/4885NPC1 141/4885 |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | CYP2A6 4210/4885KEAP1 2428/4885NPC1 4635/4885 |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP2A6 1242/4885KEAP1 38/4885NPC1 141/4885 |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP2A6 1242/4885KEAP1 38/4885NPC1 141/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | CYP2A6 1242/4885KEAP1 38/4885NPC1 141/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP2A6 1242/4885KEAP1 38/4885NPC1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.